Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study.

BMC Nephrol 2012 Jun 15;13:40. Epub 2012 Jun 15.

Monash University, Melbourne, Australia.

Background: Anaemia of chronic kidney disease increases the risk of death and adverse events, but can be managed using erythropoiesis stimulating agents (ESAs). However, recent evidence suggests that targeting a higher haemoglobin concentration ([Hb]) increases mortality risk, and both higher [Hb] targets and ESA doses have been implicated. Nonetheless, a causative role has not been demonstrated, and this potential relationship requires further appraisal in such a complex patient group.

Methods: The relationship between the haematopoietic response to ESAs and patient survival in 302 stable, prevalent dialysis patients was explored in a prospective, single-centre study. Clinical and laboratory parameters influencing mortality and ESA resistance were analysed. Patients were stratified into 5 groups, according to their [Hb] and ESA dosage, and were followed for 2 years.

Results: Little difference in co-morbidities between groups was identified. 73 patients died and 36 were transplanted. Initial analysis suggested a direct relationship between mortality and ESA dosage. However, Cox proportional hazards multivariate analysis demonstrated mortality risk was associated only with age (adjusted HR per year: 1.061, 95% CI 1.031-1.092), dialysis duration (adjusted HR: 1.010, 95% CI 1.004-1.016), peripheral vascular disease (adjusted HR: 1.967, 95% CI 1.083-3.576) and CRP (adjusted HR: 1.024, 95% CI 1.011-1.039). Mortality was increased in patients poorly responsive to ESAs (55.5%).

Conclusion: ESA dose does not appear to contribute substantially to mortality risk in dialysis patients. Instead, age and co-morbidities appear to be the critical determinants. A poor response to ESAs is a marker of overall poor health status.

Download full-text PDF

Source
http://bmcnephrol.biomedcentral.com/articles/10.1186/1471-23
Publisher Site
http://dx.doi.org/10.1186/1471-2369-13-40DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468396PMC
June 2012
25 Reads

Publication Analysis

Top Keywords

mortality risk
12
dialysis patients
12
mortality esa
8
esa dose
8
esa dosage
8
response esas
8
mortality
7
esa
6
patients
6
initial analysis
4
transplanted initial
4
analysis suggested
4
groups identified
4
difference co-morbidities
4
co-morbidities groups
4
identified patients
4
patients died
4
died transplanted
4
relationship mortality
4
multivariate analysis
4

References

(Supplied by CrossRef)

F Locatelli et al.
Nephrol Dial Transplant 2004

RN Foley et al.
Am J Kidney Dis 1996

AJ Collins et al.
J Am Soc Nephrol 2001

TB Drueke et al.
Normalizationof hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006

AK Singh et al.
N Engl J Med 2006

A Besarab et al.
N Engl J Med 1998

MA Pfeffer et al.
N Engl J Med 2009

AK Singh et al.
Curr Opin Nephrol Hypertens 2010

AT Kausz et al.
Am J Kidney Dis 2005

DJ Cottera et al.
Journal of Clinical Epidemiology 2004

Y Zhang et al.
Am J Kidney Dis 2004

Similar Publications